Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.020
+0.051 (5.30%)
At close: May 12, 2025, 4:00 PM
0.8000
-0.2200 (-21.57%)
After-hours: May 12, 2025, 6:46 PM EDT
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 5.26, with a low estimate of 1.05 and a high estimate of 7.00. The average target predicts an increase of 415.69% from the current stock price of 1.02.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coherus BioSciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +586.27% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | +2.94% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +586.27% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +586.27% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +488.24% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
101.17M
from 266.96M
Decreased by -62.10%
Revenue Next Year
98.97M
from 101.17M
Decreased by -2.17%
EPS This Year
-1.15
from 0.25
EPS Next Year
-1.00
from -1.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 113.4M | 167.0M | 208.0M | ||
| Avg | 101.2M | 99.0M | 109.0M | ||
| Low | 85.8M | 27.2M | 31.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -57.5% | 65.0% | 110.1% | ||
| Avg | -62.1% | -2.2% | 10.1% | ||
| Low | -67.9% | -73.1% | -67.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.05 | -0.83 | -0.32 | ||
| Avg | -1.15 | -1.00 | -0.62 | ||
| Low | -1.20 | -1.13 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.